PDF(Pubmed)
Abstract：
UNASSIGNED: This meta-analysis aims to examine differences in biochemical markers of bone metabolism between individuals with type 2 diabetes (T2DM) and non-T2DM control groups.
UNASSIGNED: Two independent evaluators searched five databases: PubMed, EMBASE, EBSCOhost, Web of Science, and the Cochrane Library. We aimed to identify observational studies investigating the impact of T2DM on biochemical markers of bone metabolism. Literature retrieval covered the period from the establishment of the databases up to November 2022. Studies were included if they assessed differences in biochemical markers of bone metabolism between T2DM patients and non-T2DM control groups using cross-sectional, cohort, or case-control study designs.
UNASSIGNED: Fourteen studies were included in the analysis, comprising 12 cross-sectional studies and 2 cohort studies. Compared to the non-T2DM control group, T2DM patients showed reduced levels of Osteocalcin and P1NP, which are markers of bone formation. Conversely, levels of Alkaline phosphatase and Bone-specific alkaline phosphatase, other bone formation markers, increased. The bone resorption marker CTX showed decreased levels, while TRACP showed no significant difference.
UNASSIGNED: In individuals with T2DM, most bone turnover markers indicated a reduced rate of bone turnover. This reduction can lead to increased bone fragility despite higher bone mineral density, potentially increasing the risk of osteoporosis.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php? identifier CRD42022366430.
UNASSIGNED: Two independent evaluators searched five databases: PubMed, EMBASE, EBSCOhost, Web of Science, and the Cochrane Library. We aimed to identify observational studies investigating the impact of T2DM on biochemical markers of bone metabolism. Literature retrieval covered the period from the establishment of the databases up to November 2022. Studies were included if they assessed differences in biochemical markers of bone metabolism between T2DM patients and non-T2DM control groups using cross-sectional, cohort, or case-control study designs.
UNASSIGNED: Fourteen studies were included in the analysis, comprising 12 cross-sectional studies and 2 cohort studies. Compared to the non-T2DM control group, T2DM patients showed reduced levels of Osteocalcin and P1NP, which are markers of bone formation. Conversely, levels of Alkaline phosphatase and Bone-specific alkaline phosphatase, other bone formation markers, increased. The bone resorption marker CTX showed decreased levels, while TRACP showed no significant difference.
UNASSIGNED: In individuals with T2DM, most bone turnover markers indicated a reduced rate of bone turnover. This reduction can lead to increased bone fragility despite higher bone mineral density, potentially increasing the risk of osteoporosis.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php? identifier CRD42022366430.
摘要：
■这项荟萃分析旨在检查2型糖尿病（T2DM）患者和非T2DM对照组之间骨代谢生化指标的差异。
■两个独立的评估者搜索了五个数据库：PubMed，EMBASE,EBSCOhost,WebofScience,还有Cochrane图书馆.我们的目的是确定研究T2DM对骨代谢生化标志物影响的观察性研究。文献检索涵盖了从数据库建立到2022年11月的时期。如果他们使用横断面评估T2DM患者和非T2DM对照组之间骨代谢生化标志物的差异，队列,或病例对照研究设计。
■分析中包括14项研究，包括12项横断面研究和2项队列研究。与非T2DM对照组相比,2型糖尿病患者骨钙蛋白和P1NP水平降低,它们是骨形成的标志。相反，碱性磷酸酶和骨特异性碱性磷酸酶的水平，其他骨形成标记，增加。骨吸收标志物CTX显示水平下降，而TRACP则无显著性差异。
■在患有T2DM的个体中，大多数骨转换标志物表明骨转换速率降低。尽管骨矿物质密度较高，但这种减少会导致骨脆性增加。可能增加骨质疏松症的风险。
系统审查注册：https://www。crd.约克。AC.uk/prospro/display_record.php?标识符CRD42022366430。
■两个独立的评估者搜索了五个数据库：PubMed，EMBASE,EBSCOhost,WebofScience,还有Cochrane图书馆.我们的目的是确定研究T2DM对骨代谢生化标志物影响的观察性研究。文献检索涵盖了从数据库建立到2022年11月的时期。如果他们使用横断面评估T2DM患者和非T2DM对照组之间骨代谢生化标志物的差异，队列,或病例对照研究设计。
■分析中包括14项研究，包括12项横断面研究和2项队列研究。与非T2DM对照组相比,2型糖尿病患者骨钙蛋白和P1NP水平降低,它们是骨形成的标志。相反，碱性磷酸酶和骨特异性碱性磷酸酶的水平，其他骨形成标记，增加。骨吸收标志物CTX显示水平下降，而TRACP则无显著性差异。
■在患有T2DM的个体中，大多数骨转换标志物表明骨转换速率降低。尽管骨矿物质密度较高，但这种减少会导致骨脆性增加。可能增加骨质疏松症的风险。
系统审查注册：https://www。crd.约克。AC.uk/prospro/display_record.php?标识符CRD42022366430。
